Tweets

US nationwide claims data study of CV outcomes (MACE) in #RA based on b/tsDMARD (n=34375) exposures (71% TNFi, 10% JAKi, 8% ABA, 5% RTX, 5% IL-6i). Compared to TNFi, RTX (HR 1.5) & IL-6i (HR 1.3) had numerically higher, but not statistically significant, MACE risk.… https://t.co/GXunfMY3US https://t.co/XYZPt0kzGE
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

Srudy of 558 #RA pts finds GERD symptoms were significantly w/ higher TJC28 and VAS scores and lower use of MTX (but not related to NSAID or steroid use). GERD Sxs may impact MTX dosing and Dz activity measures in RA https://t.co/2H8RUNywlG https://t.co/ZBSlTL1ZA3
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

JAMA Case: A Woman With Painful Digital Ulcers - What would you order next?
- chest CT w/ myositis-specific autoAb panel
- dsDNA
- SCL-70 & Centromere Abs
- muscle biopsy https://t.co/9T8mNDdJTs https://t.co/pTphzcuZKF
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

Seeing Beyond the Surface: Salivary Gland Ultrasound in IgG4 Related Disease
Presentation by Dr. Amy Trang at the Rheumatology Winter Clinical Symposia - Feb 2025.
https://t.co/DLXKCRz3fF https://t.co/lfobyjElFG
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/29CG4bwlYR
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

Increased L-33 linked to SLE. Study of 120 #SLE vs 60 controls. IL-33 levels signif higher in SLE (258.7 vs 78.3, p < 0.001) & correlated w/ SLEDAI (r = 0.68, p < 0.001) & organ damage (r = 0.45, p < 0.01) & renal dz (p < 0.01). https://t.co/8dbH6u2s1r https://t.co/SzKWy5Xbv1
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

AI-assisted diagnosis for immunological disease
A novel machine learning framework – Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune… https://t.co/gAViSbzreI https://t.co/IFXObUZe2s
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

CRP and Hidradenitis Supprativa
A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.… https://t.co/VxFRjt3cRw https://t.co/rdNIvzMaP8
Dr. John Cush @RheumNow ( View Tweet )
1 month 3 weeks ago

Eric Dein @ericdeinmd
Active Morphea: - MTX +/- steroids. If not effective, MMF/RTX/ABA - Topicals for circumscribed - Phototherapy Most pts achieve remission in active in 1 year Inactive morphea - Can address with PT, pain rx, psychological support, plastic surgery fat… https://t.co/wEnlo6vtAB https://t.co/4uJYC9HaS1
Dr. John Cush @RheumNow ( View Tweet )
2 months ago

Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025
Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA
FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/9er7TkNXpK https://t.co/N6sal9URv3
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 months ago

Risk for Serious Infection with Low-Dose Glucocorticoids in RA
https://t.co/5frAX3W7Hz https://t.co/PHeqCacxKa
Dr. John Cush @RheumNow ( View Tweet )
2 months ago

Deucravacitinib in Psoriasis - 5 Year Outcomes
BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter… https://t.co/as7QR8RTyx https://t.co/yNluBPR7fO
Dr. John Cush @RheumNow ( View Tweet )
2 months ago